BioSpace News Archive

Forbes highlights its “30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.

Two different companies, cardiac fibrosis RNA company HAYA Therapeutics and COVID-19 bispecific player RenBio, launched today with funding rounds designed to push them toward the clinic.

Eli Lilly’s SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.

The team has taken a fundamentally new approach to Alzheimer’s, and it centers around the hypothesis that there are multiple drivers causing the disease.

The growing prevalence of chronic diseases, infections, and disorders are urging many individuals to get tested for any ailments or health problems at an earlier stage.

High reliance on radiotherapy for cancer treatment is improving the demand for radiochemical synthesizers, prompting manufacturers to develop advanced products

First clinical trial from Crescendo’s proprietary pipeline of novel, targeted T cell enhancing Humabody® therapeutics; initial clinical data expected in 2022

HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs, announced the successful closing of its CHF 18 million seed round.

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that results from a real-world optical coherence tomography imaging study of coronary OAS patients were released at EuroPCR 2021.

Pfizer Inc. and BioNTech SE announced that the BioNTech Europe GmbH has entered into an agreement with Turkey’s Ministry of Health to supply 60 million additional doses of the companies’ COVID-19 vaccine, with an option for an additional 30 million doses.